LONDON -- Stock index futures at 7 a.m. EDT indicate that the Dow Jones Industrial Average (DJINDICES: ^DJI ) may open 0.26% higher this morning following a 207-point gain on Friday, while the S&P 500 (SNPINDEX: ^GSPC ) may open 0.35% higher. CNN's Fear & Greed Index has recovered to 46, or "neutral," after closing at 32, or "fear," on Friday.
European markets were broadly unchanged this morning at the start of what is expected to be quiet day, with no major economic reports due in the U.S or Europe. Overnight news that Japan's first-quarter GDP growth was upgraded from 3.5% to 4.1% helped Japan's Nikkei 225 rebound to a 4.9% gain, and most other Asian markets closed slightly higher after last week's losses. In London, the FTSE 100 is up almost 1% as of 7:35 a.m. EDT, while the German DAX is up 0.9 %. The FTSE was held back by falls for resource stocks, which weakened on news that consumer price-inflation in China dropped 2.1% in May from 2.4% in April, missing consensus forecasts of 2.5%. Falling inflation is likely to indicate weak underlying demand for key commodities.
5 Best Communications Equipment Stocks To Own Right Now: Alnylam Pharmaceuticals Inc.(ALNY)
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its core product programs under clinical or pre-clinical development include ALN-TTR, a Phase I clinical trial program for the treatment of transthyretin-mediated amyloidosis; ALN-APC, a Phase I clinical trial program for the treatment of hemophilia; ALN-PCS for the treatment of severe hypercholesterolemia; ALN-HPN, a pre-clinical development for the treatment of refractory anemia; and ALN-TMP, a pre-clinical development for the treatment of hemoglobinopathies, including beta-thalassemia and sickle cell anemia. The company?s partner-based programs comprise ALN-RSV01, a Phase II clinical trial program for the treatment of respiratory syncytial virus infection; ALN-VSP, a Phase I clinical trial completed program for the treatment of liver cancers; and ALN-HTT, a pre-clinical development for the treatment of Huntington?s disease. It has strategic alliances with Novartis Pharma AG; F. Hoffmann-La Roche Ltd; Takeda Pharmaceutical Company Limited; Isis Pharmaceuticals, Inc.; Medtronic Inc.; Kyowa Hakko Kirin Co., Ltd.; and Cubist Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Advisors' Opinion:- [By Sean Williams]
On the clinical data front, Alnylam Pharmaceuticals (NASDAQ: ALNY ) and Inovio Pharmaceuticals (NYSEMKT: INO ) both put investors in their happy place.
- [By Ben Levisohn]
Markey rates the stock a Buy with an $11 price target. Shares of MannKind have jumped 14% to $7.85 today. The SPDR Biotech ETF (XBI) has gained 0.7% to $119.85 today, while Alnylam Pharmaceuticals (ALNY) has gained 1% to $49.05, NPS Pharmaceuticals (NPSP) has fallen 4.1% to $23.56, and InterMune (ITMN) has risen 2.6% to $14.89.
Best Asian Companies For 2014: Juniper Networks Inc (JNPR)
Juniper Networks, Inc. (Juniper Networks), incorporated on September 10, 1996, designs, develops, and sells products and services that together provide its customers with network infrastructure. It operates in two segments: Infrastructure and Service Layer Technologies (SLT). The Company�� Infrastructure segment primarily offers routing and switching products that are used to control and direct network traffic from the core, through the edge, aggregation, and the customer premise equipment level. Infrastructure products include its Internet protocol (IP) routing, carrier Ethernet routing portfolio, and Ethernet switching portfolio. In addition, the Infrastructure segment offers a complete wireless local area network (WLAN) solution. Its SLT segment offers solutions that meet a range of its customers' priorities, from protecting the users, applications and data on the network itself to providing network services across a distributed infrastructure. Effective September 13, 2013, Juniper Networks, Inc. acquired Contrail Networks Inc.
Brilliant is a supplier of packet-based, network synchronization equipment and monitoring solutions. During the year ended December 31, 2011, the Company introduced its network architecture and fabric technology for the data center, QFabric. It serves the high-performance networking requirements of global service providers, enterprises, and public sector organizations. The Company�� open cross-network software platform includes the Junos operating system (Junos OS), Junos Space network application platform, and Junos Pulse integrated network client. The Company offers a product portfolio that spans routing, switching, security, application access, and mobility device security.
Infrastructure Products
The Company�� T Series core routers are primarily designed for core IP infrastructures and are also being sold into the multi-service environment. Its PTX Series is a large capacity (8 and 16 tera-bits per second) MPLS-optimized packe! t transport switch for the core networks, of content service providers and Tier 1 service providers, with high throughout of packet traffic. The Company�� E Series products are a full featured platform designed for the network edge with support for carrier-class routing, broadband subscriber management services, and a set of IP services. The MX Series is a product family developed to address emerging Ethernet network architectures and services in service provider and enterprise networks. The Company�� EX Series family extends its product portfolio running its Junos OS to address the Ethernet switch market. Ethernet is a used technology, which is used to transport information in enterprise networks. Infrastructure Products also includes QFabric Products and WLAN product.
SLT Products
SLT Products include Services Gateway, Integrated Firewall, and VPN Solutions, Secure Access Appliances, Secure Access Appliances, IDP Series Appliances and Identity and Policy Control Solutions. The Company�� SRX Series of dynamic services gateways, running its Junos software, provides firewall/VPN and combines routing, switching, and security functionality. The series is designed to meet network and security requirements for data center consolidation, rapid managed services deployments, and aggregation of security services. Its firewall and VPN systems and appliances are designed to provide integrated firewall, VPN, and denial of service protection capabilities for both enterprise environments and service provider network infrastructures. These products range from its SSG product series, which combines LAN/WAN routing capabilities with threat management features, such as antivirus, anti-spam, and Web filtering technologies, to its ISG and NetScreen Series firewall and VPN systems, which are designed to deliver security in medium/large enterprises, carrier networks, and data centers.
The Company�� Junos Pulse, Junos Pulse Mobile Security Suite, and SA Series SSL VPN appliances,! designed! for use in companies of all sizes, are used to provide secure access to corporate resources for remote and mobile users from any Web-enabled device, regardless of location. Its portfolio of identity and policy control solutions integrates subscriber privileges, application requirements, and business policies with the IP network infrastructure.
The Company competes with Cisco Systems, Inc. (Cisco), Alcatel-Lucent, Brocade Communications Systems, Inc. (Brocade), Extreme Networks, Inc., Hewlett Packard Company (HP), Huawei Technologies Co., Ltd. (Huawei), Check Point Software Technologies, F5 Networks, Inc., Palo Alto Networks, Inc., and Riverbed Technology, Inc.
Advisors' Opinion:- [By Lisa Levin]
Juniper Networks (NYSE: JNPR) shares jumped 7.98% to reach a new 52-week high of $25.41 following Elliott headlines.
Posted-In: 52-Week HighsNews Intraday Update Markets Movers
- [By MONEYMORNING]
In addition to weakness in emerging markets, which the company acknowledged last year, rivals Juniper Networks Inc. (NYSE: JNPR) and F5 Networks, Inc. (Nasdaq: FFIV) have been nibbling at Cisco's market share.
Best Asian Companies For 2014: Material Sciences Corporation(MASC)
Material Sciences Corporation, together with its subsidiaries, engages in the design, manufacture, and marketing of material-based solutions for acoustical and coated applications in the United States and internationally. It offers acoustical material-based solutions, which include multilayer composites consisting of metals, polymers, and other coated materials used to manage noise and vibration in automotive body panel parts, brake dampers, engine parts, appliances, and computer disk drives, as well as heating, ventilating, and air conditioning products. The company also provides coated material-based solutions that comprise painted, electrogalvanized protective, decorative, and functional coatings applied to coils of metals for automotive fuel tanks, building products, gaskets, appliances, and lighting fixtures. Material Sciences Corporation primarily serves customers in the automotive, appliance, building and construction, lighting, and electronic markets. The company m arkets its products, services, and technologies through sales and marketing organization, as well as through agents and licensees. Material Sciences Corporation was founded in 1971 and is headquartered in Elk Grove Village, Illinois.
Advisors' Opinion:- [By Monica Gerson]
Material Sciences (NASDAQ: MASC) is projected to report its Q2 earnings at $0.16 per share.
Blackhawk Network Holdings (NASDAQ: HAWK) is estimated to report its Q3 earnings at $0.05 per share on revenue of $210.94 million.
Best Asian Companies For 2014: Flamel Technologies S.A.(FLML)
Flamel Technologies S.A., a biopharmaceutical company, engages in the development and commercialization of controlled-release therapeutic products based on its proprietary polymer based technology in the United Kingdom, Ireland, the United States, France, and Europe. The company develops nanogel Medusa technology, which is intended to provide controlled release following injection of therapeutic proteins, peptides, and other molecules; a microparticle adaptation of the Medusa platform that is intended for use in the delivery of smaller proteins and peptides; and Micropump technology, a microparticle technology for oral administration of small molecule drugs with applications in controlled-release, taste-masking, and bioavailability enhancement; and Trigger-Lock technology, an adaptation based on Micropump technology, which is intended to minimize the misuse and abuse of medications subject to abuse. Its principal product based on Micropump technology is Coreg CR, which is intended for the treatment of moderate to severe heart failure and left ventricular dysfunction following myocardial infarction. The company?s products under development based upon Medusa technology include Interferon-alpha, a naturally occurring protein that the body uses for the treatment of Hepatitis C virus and as a immune response; and FT-105, an injectable insulin formulation for diabetic patients. Its products based on its Micropump technology comprise LiquiTime for the elderly and pediatric patient patients, or others who have difficulty swallowing. The company has strategic alliance with Baxter International, Inc.; GlaxoSmithKline; Merck Serono; and Pfizer Inc, as well as has a joint development agreement with Digna Biotech, S.L. Flamel Technologies S.A. was founded in 1990 and is headquartered in Venissieux, France.
Advisors' Opinion:- [By Anna Prior]
Flamel Technologies SA(FLML) said the U.S. Food and Drug Administration has approved the company’s new drug application for Vazculep, an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. American depositary shares rose 5.1% to $14.78 in premarket trading.
Best Asian Companies For 2014: Pharmerica Corporation(PMC)
Pharmerica Corporation operates as an institutional pharmacy services company in the United States. It offers services to healthcare facilities and provides management pharmacy services to hospitals. The company purchases, repackages, and dispenses prescription and non-prescription pharmaceuticals in accordance with physician orders and delivers such medication to healthcare facilities for administration to individual patients and residents. It also provides consultant pharmacist services for customers to comply with the federal and state regulations applicable to nursing homes; and medical records services. In addition, the company offers various ancillary services, such as infusion therapy products and services; and hospital pharmacy management services, including hospital pharmacy operations, regulatory and financial management services, and clinical pharmacy programs to various hospitals. PharMerica Corporation operates approximately 95 institutional pharmacies in 44 s tates and provides pharmacy management services to 91 hospitals. Its customers primarily include institutional healthcare providers, such as skilled nursing facilities, nursing centers, assisted living facilities, hospitals, and other long-term alternative care settings. The company is headquartered in Louisville, Kentucky.
Advisors' Opinion:- [By Sean Williams]
What: Shares of PharMerica (NYSE: PMC ) , a pharmacy services company, jumped as much as 11% after reporting better-than-expected first-quarter results.
- [By Josh Arnold]
PharMerica Corporation (PMC) is a pharmacy services company that operates in several segments in the US. The company offers services to healthcare facilities, pharmacy management services and specialty infusion to patients outside of hospitals. PMC's primary customers are assisted living centers, hospitals, and other long term care facilities. The company services just under 200 locations in 45 states in the US and produces about $1.7 billion in annual revenue. With shares near the bottom of their 52 week range following a nasty selloff, is there any value in PMC or is it a classic trap? I'll argue here that PMC's structural tailwinds for earnings including demographics and consumer preference shifts will increase PMC's ability to convert revenue into profit and drive the stock higher.
No comments:
Post a Comment